Our data also indicate that in B-ALL, deletions of 6q may flag a metabolic vulnerability, which could be exploited by specific activation of FOXO3 or treatment with inhibitors of glycolysis such as the TXNIP agonist 3-O-methyleglucose [57]. The gene discussed is TXNIP; the disease is acute lymphoblastic leukemia.